Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.03, for a total transaction of $27,637.58. Following the sale, the insider now owns 80,818 shares in the company, valued at approximately $2,265,328.54. This represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Trading Up 0.3 %

Castle Biosciences stock opened at $25.09 on Friday. The firm has a market cap of $702.77 million, a price-to-earnings ratio of 125.46 and a beta of 0.92. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The firm’s 50 day moving average price is $29.40 and its two-hundred day moving average price is $28.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same period in the previous year, the firm posted ($0.26) EPS. On average, research analysts predict that Castle Biosciences, Inc. will post 0.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors have recently bought and sold shares of the stock. Quest Partners LLC lifted its stake in Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after buying an additional 1,522 shares in the last quarter. US Bancorp DE raised its holdings in shares of Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after acquiring an additional 4,383 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Castle Biosciences in the 3rd quarter valued at approximately $140,000. Assetmark Inc. boosted its stake in Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after purchasing an additional 748 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after purchasing an additional 2,093 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

CSTL has been the topic of several research analyst reports. KeyCorp raised their target price on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Robert W. Baird boosted their target price on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research note on Thursday, January 2nd. BTIG Research boosted their price objective on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Canaccord Genuity Group raised their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences has an average rating of “Buy” and a consensus price target of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.